Fulranumab, initially explored as AMG-403 subsequently JNJ-42160443, represents a intriguing therapeutic agent aimed at soluble TNF receptors. The mechanism depends on neutralizing these receptors, thereby https://www.targetmol.com/compound/fulranumab